Argenx SE (ARGX) has experienced impressive growth in the recent period, buoyed by increased sales of its
Vyvgart (efgartigimod alfa) medication. A late-stage trial success resulted in preparations for an FDA filing to push Vyvgart into broader myasthenia gravis populations. A partnership with
FUJIFILM Biotechnologies was expanded to augment Vyvgart production, further strengthening Argenx's position in the market. The firm also announced a $1.5 billion agreement with
Unnatural Products to develop macrocyclic peptides for 'undruggable' targets. Argenx further highlighted its immunology innovation at the 2025 AANEM Annual Meeting and MGFA Scientific Session. Encouraging financial results have been reported for Q3 2025, with Citi, H.C. Wainwright, and other firms maintaining a bullish perspective on Argenx. Investors anticipate increased ROI due to expanding partnerships, strong sales, and product innovation. Aiming to raise myasthenia gravis awareness, Argenx has collaborated with Tennis legend
Monica Seles, including a partnership for the U.S. Open.
argenx News Analytics from Thu, 10 Apr 2025 07:00:00 GMT to Sat, 15 Nov 2025 19:06:01 GMT -
Rating 8
- Innovation 7
- Rumor -2
